Tzield® (teplizumab-mzwv)

Published: March 27, 2024 in Drug

Full Name	Tzield® (teplizumab-mzwv)
Drug	Tzield
Manufacturer	Sanofi
Route of Administration	Intravenous
Site of Care	Home or Healthcare Facility
Approved Indication	Indicated to: Delay the onset of Stage 3 type 1 diabetes (T1D) in adult and pediatric patients 1 year of age and older with Stage 2 T1D Delay the decline in endogenous insulin production in pediatric patients aged 8 to 17 years recently diagnosed with Stage 3 T1D. This indication is approved under accelerated approval based on evidence of reduced C-peptide decline. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s).
Disease	Type 1 Diabetes (T1D)
Therapeutic Area	Endocrinology & Bone Specialty
Enrollment Form Link	Tzield Enrollment Form
Phone Number	800-670-5321
Fax Number	877-655-4364
Product Website	tzield.com